Press Release Archive
-
Johnson & Johnson Innovation Names Winners of Inaugural Champions of Science – Africa Storytelling ChallengeJohnson & Johnson Innovation Names Winners of Inaugural Champions of Science – Africa Storytelling Challenge
-
Johnson & Johnson to Participate in the 8th Annual SVB Leerink Global
Healthcare ConferenceJohnson & Johnson to Participate in the 8th Annual SVB Leerink Global
Healthcare Conference -
Janssen Announces Preliminary Results from Phase 2 GALAHAD Study in Adults with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Pathway Defects (DRD)Janssen Announces Preliminary Results from Phase 2 GALAHAD Study in Adults with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Pathway Defects (DRD)
-
Johnson & Johnson Announces Agreement to Acquire Auris Health, Inc.Johnson & Johnson Announces Agreement to Acquire Auris Health, Inc.
-
FDA Advisory Committee Recommends Approval of SPRAVATOTM (esketamine) Nasal Spray CIII for Adults with Treatment-Resistant DepressionFDA Advisory Committee Recommends Approval of SPRAVATOTM (esketamine) Nasal Spray CIII for Adults with Treatment-Resistant Depression
-
U.S. FDA Approves DARZALEX® (daratumumab) Split-Dosing RegimenU.S. FDA Approves DARZALEX® (daratumumab) Split-Dosing Regimen
-
Johnson & Johnson to Participate in the 2019 CAGNY ConferenceJohnson & Johnson to Participate in the 2019 CAGNY Conference
-
First Atrial Fibrillation Patient Treated in Biosense Webster U.S. IDE Study Evaluating High Power, Short Duration Ablation CatheterFirst Atrial Fibrillation Patient Treated in Biosense Webster U.S. IDE Study Evaluating High Power, Short Duration Ablation Catheter
-
Janssen Enters Worldwide Collaboration and License Agreement with MeiraGTx to Develop Gene Therapy Programs for Inherited Retinal DiseasesJanssen Enters Worldwide Collaboration and License Agreement with MeiraGTx to Develop Gene Therapy Programs for Inherited Retinal Diseases
-
Janssen Announces ERLEADA® (apalutamide) Phase 3 TITAN Study Unblinded as Dual Primary Endpoints Achieved in Clinical Program Evaluating Treatment of Patients with Metastatic Castration-Sensitive Prostate CancerJanssen Announces ERLEADA® (apalutamide) Phase 3 TITAN Study Unblinded as Dual Primary Endpoints Achieved in Clinical Program Evaluating Treatment of Patients with Metastatic Castration-Sensitive Prostate Cancer